01952.HK
Everest Medicines Limited
HKSE · Healthcare · Biotechnology · CN
HKD 31.98
−1.54%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.4B | 1.7B | 706.7M | 125.9M | 12.8M |
| Cost of Revenue | 726.6M | 524.8M | 177.8M | 34.4M | 4.6M |
| Gross Profit | 1.7B | 1.2B | 528.9M | 91.5M | 8.1M |
| Operating Expenses | |||||
| R&D Expense | 571.9M | 511.0M | 528.0M | 540.1M | 809.7M |
| SG&A Expense | 1.2B | 1.1B | 758.1M | 396.6M | 603.2M |
| General & Admin Expense | 314.3M | 276.5M | 250.1M | 165.2M | 276.5M |
| Selling & Marketing Expense | 923.3M | 780.5M | 508.1M | 231.4M | 326.7M |
| Other Expenses | — | — | 359.8M | 87.6M | (1.1B) |
| Total Operating Expenses | 1.8B | 1.6B | 1.6B | 1.0B | 264.9M |
| Cost and Expenses | 2.5B | 2.1B | 1.8B | 1.1B | 269.6M |
| Operating Income (EBIT) | (127.8M) | (386.2M) | (1.1B) | (932.7M) | (256.8M) |
| Non-Operating | |||||
| Interest Income | — | 63.6M | 95.2M | 107.7M | 38.5M |
| Interest Expense | — | 22.7M | 22.2M | 23.1M | 5.6M |
| Net Interest Income | 80.0M | 40.9M | 73.0M | 84.6M | 32.9M |
| Other Non-Op Income/Expense | (196.4M) | (212.1M) | 75.7M | 88.3M | 9.5M |
| Non-Operating Income (excl Interest) | (28.1M) | (42.3M) | (336.8M) | (111.3M) | (15.1M) |
| EBT (Pre-Tax Income) | (324.2M) | (598.4M) | (1.0B) | (844.5M) | (247.3M) |
| Income Tax Expense | 330.9M | (292.8M) | — | — | 8.0K |
| Bottom Line | |||||
| Net Income | (53.9M) | (297.8M) | (1.0B) | (844.5M) | (247.3M) |
| Earnings from Cont. Ops | (53.9M) | (297.8M) | (1.0B) | (844.5M) | (247.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (53.9M) | (297.8M) | (1.0B) | (844.5M) | (247.3M) |
| Per Share | |||||
| Basic EPS | (HK$0.16) | (HK$0.89) | (HK$3.24) | (HK$2.70) | (HK$0.83) |
| Diluted EPS | (HK$0.16) | (HK$0.89) | (HK$3.24) | (HK$2.70) | (HK$0.83) |
| Revenue Per Share | HK$8.10 | HK$5.10 | HK$2.20 | HK$0.40 | HK$0.04 |
| Shares | |||||
| Basic Shares Outstanding | 297.2M | 334.6M | 320.9M | 313.1M | 297.6M |
| Diluted Shares Outstanding | 297.2M | 336.5M | 320.9M | 313.1M | 297.6M |
| Profitability Metrics | |||||
| EBITDA | 38.8M | (211.2M) | (670.0M) | (744.6M) | (198.9M) |
| D&A | 138.6M | 132.7M | 110.2M | 76.8M | 42.8M |
| EBIT | (99.7M) | (343.9M) | (780.2M) | (821.4M) | (241.7M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026